Fecal Calprotectin as a Biomarker for Diagnosis and Monitoring of Gastrointestinal Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
Posted inClinical Updates Gastroenterology Hematology-Oncology news

Fecal Calprotectin as a Biomarker for Diagnosis and Monitoring of Gastrointestinal Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Fecal calprotectin offers a non-invasive, dynamic biomarker to predict, diagnose, and monitor GI-GVHD post-allo-HSCT, correlating with endoscopic severity and treatment response, but requires integrated clinical interpretation due to limited specificity.
Advancing Donation After Circulatory Death Liver Transplantation: National Evidence Supporting Normothermic Regional and Machine Perfusion as Standards of Care
Posted inGastroenterology General Surgery news

Advancing Donation After Circulatory Death Liver Transplantation: National Evidence Supporting Normothermic Regional and Machine Perfusion as Standards of Care

A comprehensive national study shows both normothermic regional perfusion (NRP) and normothermic machine perfusion (NMP) significantly improve graft survival in DCD liver transplantation, supporting their adoption as complementary standards of care in the U.S.
PRDM9 Deficiency Identifies a Predominant Molecular Subgroup in Sporadic Hirschsprung Disease and Enables Blood-based Risk Stratification
Posted inGastroenterology news Pediatrics

PRDM9 Deficiency Identifies a Predominant Molecular Subgroup in Sporadic Hirschsprung Disease and Enables Blood-based Risk Stratification

A 2026 Gastroenterology study links PRDM9 deficiency to ectopic DNA breaks, mosaic promoter deletions, and impaired enteric neuronal differentiation in sporadic Hirschsprung disease, while introducing a blood-based molecular score that improves case discrimination, especially when combined with polygenic risk.
Primary vs Specialist Palliative Care in End-Stage Liver Disease: Interpreting the 2026 Cluster Randomized Trial in the Broader Evidence Base
Posted inClinical Updates Gastroenterology Internal Medicine news

Primary vs Specialist Palliative Care in End-Stage Liver Disease: Interpreting the 2026 Cluster Randomized Trial in the Broader Evidence Base

A major 2026 cluster randomized trial shows that palliative care delivered by trained hepatologists is noninferior to specialist palliative care for improving quality of life in end-stage liver disease, supporting scalable integrated models for cirrhosis and hepatocellular carcinoma.